FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001882118> ?p ?o ?g. }

• W2001882118 endingPage "255" @default.
• W2001882118 startingPage "251" @default.
• W2001882118 abstract "Lung Cancer ManagementVol. 2, No. 4 CommentaryRadiosensitizing biological modifiers enhancing efficacy in non-small-cell lung cancer treated with radiotherapyGeorg Holgersson, Stefan Bergström, Simon Ekman, Daniel Brattström, Roger Henriksson, Per Edlund & Michael BergqvistGeorg Holgersson* Author for correspondenceDepartment of Oncology, Entrance 78, Uppsala University Hospital, SE-751 85 Uppsala, Sweden. Section of Oncology, Department of Radiology, Oncology & Radiation Sciences, Uppsala University Hospital, SE 751 85 Uppsala, SwedenDepartment of Oncology, Gävle Hospital, SE-801 87 Gävle, SwedenSearch for more papers by this authorEmail the corresponding author at georg.h@telia.com, Stefan BergströmDepartment of Oncology, Gävle Hospital, SE-801 87 Gävle, SwedenSearch for more papers by this author, Simon EkmanSection of Oncology, Department of Radiology, Oncology & Radiation Sciences, Uppsala University Hospital, SE 751 85 Uppsala, SwedenSearch for more papers by this author, Daniel BrattströmSection of Oncology, Department of Radiology, Oncology & Radiation Sciences, Uppsala University Hospital, SE 751 85 Uppsala, SwedenSearch for more papers by this author, Roger HenrikssonDepartment of Radiation Sciences & Oncology, Umeå University Hospital, SE-901 87 Umeå, SwedenSearch for more papers by this author, Per EdlundSection of Oncology, Department of Radiology, Oncology & Radiation Sciences, Uppsala University Hospital, SE 751 85 Uppsala, SwedenSearch for more papers by this author & Michael BergqvistSection of Oncology, Department of Radiology, Oncology & Radiation Sciences, Uppsala University Hospital, SE 751 85 Uppsala, SwedenDepartment of Oncology, Gävle Hospital, SE-801 87 Gävle, SwedenSearch for more papers by this authorPublished Online:31 Jul 2013https://doi.org/10.2217/lmt.13.25AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleReferences1 Baujat B, Bourhis J, Blanchard P et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst. Rev. (12),CD002026 (2010).Medline, Google Scholar2 Benschop K, Minnaar R, Koen G et al. Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping. Diagn. Microbiol. Infect. Dis.68(2),166–173 (2010).Crossref, Medline, CAS, Google Scholar3 Free CM, Ellis M, Beggs L, Beggs D, Morgan SA, Baldwin DR. Lung cancer outcomes at a UK cancer unit between 1998–2001. Lung Cancer57(2),222–228 (2007).Crossref, Medline, CAS, Google Scholar4 Kempner ES. Effects of high-energy electrons and gamma rays directly on protein molecules. J. Pharm. Sci.90(10),1637–1646 (2001).Crossref, Medline, CAS, Google Scholar5 McMillan TJ, Peacock JH. Molecular determinants of radiosensitivity in mammalian cells. Int. J. Radiat. Biol.65(1),49–55 (1994).Crossref, Medline, CAS, Google Scholar6 Wood RD. Nucleotide excision repair in mammalian cells. J. Biol. Chem.272(38),23465–23468 (1997).Crossref, Medline, CAS, Google Scholar7 Weinfeld M, Rasouli-Nia A, Chaudhry MA, Britten RA. Response of base excision repair enzymes to complex DNA lesions. Radiat. Res.156(5 Pt 2),584–589 (2001).Crossref, Medline, CAS, Google Scholar8 Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J. Cell. Physiol.191(1),28–41 (2002).Crossref, Medline, CAS, Google Scholar9 Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res.477(1–2),131–153 (2001).Crossref, Medline, CAS, Google Scholar10 Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res.511(2),145–178 (2002).Crossref, Medline, CAS, Google Scholar11 Holgersson G, Bergstrom S, Bergqvist M et al. Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur. J. Cancer47(16),2415–2421 (2011).Crossref, Medline, Google Scholar12 Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer59(11),1874–1881 (1987).Crossref, Medline, CAS, Google Scholar13 Saunders MI, Dische S, Barrett A, Parmar MK, Harvey A, Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br. J. Cancer73(12),1455–1462 (1996).Crossref, Medline, CAS, Google Scholar14 Hennequin C. [Association of taxanes and radiotherapy: preclinical and clinical studies]. Cancer Radiother.8(Suppl. 1),S95–S105 (2004).Crossref, Medline, Google Scholar15 Nyman J, Friesland S, Hallqvist A et al. How to improve loco-regional control in stages IIIa–b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer65(1),62–67 (2009).Crossref, Medline, CAS, Google Scholar16 Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101(36),13306–13311 (2004).Crossref, Medline, CAS, Google Scholar17 Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366(9496),1527–1537 (2005).Crossref, Medline, CAS, Google Scholar18 Tsao MS, Aviel-Ronen S, Ding K et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol.25(33),5240–5247 (2007).Crossref, Medline, Google Scholar19 Ready N, Janne PA, Bogart J et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified Phase II trial. J. Thorac. Oncol.5(9),1382–1390 (2010).Crossref, Medline, Google Scholar20 Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol.26(15),2450–2456 (2008).Crossref, Medline, CAS, Google Scholar21 Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol.10(10),1001–1010 (2009).Crossref, Medline, CAS, Google Scholar22 Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs23(5),289–304 (2009).Crossref, Medline, CAS, Google Scholar23 Zhu CQ, Da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Clin. Oncol.26(26),4268–4275 (2008).Crossref, Medline, CAS, Google Scholar24 Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372(9652),1809–1818 (2008).Crossref, Medline, CAS, Google Scholar25 Bernhard EJ, Stanbridge EJ, Gupta S et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res.60(23),6597–6600 (2000).Medline, CAS, Google Scholar26 Horn L, Pao W. EML4–ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol.27(26),4232–4235 (2009).Crossref, Medline, CAS, Google Scholar27 Martín Ureste M, Gironés Sarrió R, Montalar Salcedo J. Biomarkers in bronchopulmonary cancer. Clin. Transl. Oncol.12(2),92–99 (2010).Crossref, Medline, Google Scholar28 Balak MN, Gong Y, Riely GJ et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res.12(21),6494–6501 (2006).Crossref, Medline, CAS, Google Scholar29 Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18),1693–1703 (2010).Crossref, Medline, CAS, Google Scholar30 Sun Y, Nowak KA, Zaorsky NG et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4–ALK. Mol. Cancer Ther.12(5),696–704 (2013).Crossref, Medline, CAS, Google Scholar31 Balsara BR, Pei J, Mitsuuchi Y et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis25(11),2053–2059 (2004).Crossref, Medline, CAS, Google Scholar32 Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res.9(6),2316–2326 (2003).Medline, CAS, Google Scholar33 Ausborn NL, Le QT, Bradley JD et al. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int. J. Radiat. Oncol. Biol. Phys.83(4),e453–e464 (2012).Crossref, Medline, CAS, Google Scholar34 Sarkaria JN, Schwingler P, Schild SE et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J. Thorac. Oncol.2(8),751–757 (2007).Crossref, Medline, Google Scholar35 Mauceri HJ, Sutton HG, Darga TE et al. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncology Rep.27(5),1625–1629 (2012).Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 2, No. 4 Follow us on social media for the latest updates Metrics Downloaded 39 times History Published online 31 July 2013 Published in print August 2013 Information© Future Medicine LtdFinancial & competing interests disclosureThe authors would like to thank the Cancer Foundation at Gävle Hospital for their financial support The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2001882118 created "2016-06-24" @default.
• W2001882118 creator A5001810357 @default.
• W2001882118 creator A5018148458 @default.
• W2001882118 creator A5027622198 @default.
• W2001882118 creator A5044685097 @default.
• W2001882118 creator A5048593161 @default.
• W2001882118 creator A5051008618 @default.
• W2001882118 creator A5086525400 @default.
• W2001882118 date "2013-08-01" @default.
• W2001882118 modified "2023-09-26" @default.
• W2001882118 title "Radiosensitizing biological modifiers enhancing efficacy in non-small-cell lung cancer treated with radiotherapy" @default.
• W2001882118 cites W1500525204 @default.
• W2001882118 cites W165034771 @default.
• W2001882118 cites W1971513512 @default.
• W2001882118 cites W1980507955 @default.
• W2001882118 cites W1995805135 @default.
• W2001882118 cites W2013988606 @default.
• W2001882118 cites W2019313870 @default.
• W2001882118 cites W2020043024 @default.
• W2001882118 cites W2027459565 @default.
• W2001882118 cites W2043527294 @default.
• W2001882118 cites W2051767374 @default.
• W2001882118 cites W2058963557 @default.
• W2001882118 cites W2083027901 @default.
• W2001882118 cites W2094962376 @default.
• W2001882118 cites W2096744050 @default.
• W2001882118 cites W2096786080 @default.
• W2001882118 cites W2103225497 @default.
• W2001882118 cites W2104830962 @default.
• W2001882118 cites W2105026490 @default.
• W2001882118 cites W2113349101 @default.
• W2001882118 cites W2116298638 @default.
• W2001882118 cites W2121110745 @default.
• W2001882118 cites W2122553809 @default.
• W2001882118 cites W2132292320 @default.
• W2001882118 cites W2139236349 @default.
• W2001882118 cites W2142148449 @default.
• W2001882118 cites W2153451878 @default.
• W2001882118 cites W2153477391 @default.
• W2001882118 cites W2153865661 @default.
• W2001882118 cites W2158310120 @default.
• W2001882118 cites W2178225883 @default.
• W2001882118 doi "https://doi.org/10.2217/lmt.13.25" @default.
• W2001882118 hasPublicationYear "2013" @default.
• W2001882118 type Work @default.
• W2001882118 sameAs 2001882118 @default.
• W2001882118 citedByCount "1" @default.
• W2001882118 countsByYear W20018821182014 @default.
• W2001882118 crossrefType "journal-article" @default.
• W2001882118 hasAuthorship W2001882118A5001810357 @default.
• W2001882118 hasAuthorship W2001882118A5018148458 @default.
• W2001882118 hasAuthorship W2001882118A5027622198 @default.
• W2001882118 hasAuthorship W2001882118A5044685097 @default.
• W2001882118 hasAuthorship W2001882118A5048593161 @default.
• W2001882118 hasAuthorship W2001882118A5051008618 @default.
• W2001882118 hasAuthorship W2001882118A5086525400 @default.
• W2001882118 hasConcept C121608353 @default.
• W2001882118 hasConcept C126322002 @default.
• W2001882118 hasConcept C143998085 @default.
• W2001882118 hasConcept C2776256026 @default.
• W2001882118 hasConcept C509974204 @default.
• W2001882118 hasConcept C71924100 @default.
• W2001882118 hasConceptScore W2001882118C121608353 @default.
• W2001882118 hasConceptScore W2001882118C126322002 @default.
• W2001882118 hasConceptScore W2001882118C143998085 @default.
• W2001882118 hasConceptScore W2001882118C2776256026 @default.
• W2001882118 hasConceptScore W2001882118C509974204 @default.
• W2001882118 hasConceptScore W2001882118C71924100 @default.
• W2001882118 hasIssue "4" @default.
• W2001882118 hasLocation W20018821181 @default.
• W2001882118 hasOpenAccess W2001882118 @default.
• W2001882118 hasPrimaryLocation W20018821181 @default.
• W2001882118 hasRelatedWork W1967103478 @default.
• W2001882118 hasRelatedWork W2365632055 @default.
• W2001882118 hasRelatedWork W2372561159 @default.
• W2001882118 hasRelatedWork W2375344515 @default.
• W2001882118 hasRelatedWork W2380382254 @default.
• W2001882118 hasRelatedWork W2384708512 @default.
• W2001882118 hasRelatedWork W2390152934 @default.
• W2001882118 hasRelatedWork W2395953112 @default.
• W2001882118 hasRelatedWork W2412727163 @default.
• W2001882118 hasRelatedWork W1912371934 @default.
• W2001882118 hasVolume "2" @default.
• W2001882118 isParatext "false" @default.
• W2001882118 isRetracted "false" @default.
• W2001882118 magId "2001882118" @default.
• W2001882118 workType "article" @default.